To assess the ability of risk of malignancy index (RMI) 1 to discriminate between benign and malignant pelvic masses. Methods: Between January 2007 and December 2010, 547 women with pelvic masses were evaluated. Their medical records are reviewed here retrospectively. The sensitivity, specificity and positive and negative predictive values of the cancer antigen (CA) 125 level, ultrasound findings and menopausal status in the prediction of malignant pelvic masses were calculated and compared individually or combined using the RMI 1. Results: The receiver operating characteristic (ROC) curves of CA 125, the ultrasound score and the RMI 1 were all found to be relevant predictors of malignancy. ROC analysis of the RMI 1, CA 125 serum levels, ultrasound score and menopausal status showed areas under the curves of 0.795, 0.782, 0.784 and 0.594, respectively. The RMI 1 was found to be statistically significantly correlated with menopausal status (P = 0.001), while not statistically significantly correlated with CA 125 (P = 0.628) or the ultrasound score (P = 0.541). The RMI 1 at a cut-off of 150 -with a sensitivity of 77.9%, specificity of 81.1%, positive predictive value of 51.7% and negative predictive value of 93.4% -showed the highest performance in determining the malignant tendency of pelvic masses. Conclusion: Accepting a RMI 1 cut-off value of 150 results in statistically more significant diagnostic criteria than menopausal status for the discrimination of benign and malignant pelvic masses. (J Korean Soc Menopause 2013;19:18-25)
The accurate diagnosis of a pelvic mass is a challenge to a gynecologist before the pelvic cavity is explored by laparotomy or laparoscopy, because of pelvic masses' bizarre and atypical behavior. Pelvic masses are one of the most common clinical presentations. These masses represent a number of benign and malignant conditions. Treatment can be optimally planned if it is known beforehand whether an ovarian neoplasm is benign or malignant. The prognosis for 박정우 외. 악성 위험지수 (Risk of Malignancy Index) 1을 이용한 골반내 종양의 분석 http://dx.doi.org/10.6118/jksm.2013. 19.1.18 women with ovarian cancer may be greatly influenced by appropriate first-line therapy. 1~6 Used alone, the diagnostic accuracy of demographic, sonographic and biochemical variables is poor for clinical use. Jacobs et al. 7 developed the risk of malignancy index (RMI) for referral of relevant patients to gynecologic oncology centers. The RMI 1 was the first diagnostic model in the assessment of patients with pelvic masses. The RMI was adjusted by Tingulstad et al. 8 in 1996 (RMI 2) and again in 1999 (RMI 3). 9 The three versions of the RMI have been validated retrospectively and prospectively in different clinical studies 7~19 where a cut-off value of 200 showed the best discrimination between benign and malignant pelvic masses, with high sensitivity and specificity levels (sensitivity 51-90%, specificity 51-97%). Recently RMI 4 was introduced by Yamamoto et al. 20 Four RMIs had some different characteristics. RMI 1 was the first version as developed by Jacobs et al. 7 and gave an ultrasound score (U) of 0 when none of the ultrasound features were present, resulting in an RMI 1 of 0 regardless of the cancer antigen (CA) 125 level. But, RMI 2-4 had not ultrasound score of 0.
Yamamoto et al. 20 have published their study in which RMI 4 was created, that includes tumor size as an additional parameter.
The main advantage of four RMIs is that it is a simple scoring system that can be applied directly into clinical practice without the introduction of expensive or complicated methods (such as computed tomography scan, magnetic resonance imaging, and whole-body positron emission tomography). The RMIs can be applied in less specialized centers. The RMI 1 was the first diagnostic model that combined demographic, sonographic and biochemical data in the assessment of patients with pelvic masses.
The purpose of the present study was to assess ability of the RMI 1 to discriminate between benign and malignant pelvic masses.
Materials and Methods
This is a retrospective study. The clinical data were obtained from consecutive 547 women with pelvic masses scheduled for laparotomy or laparoscopy at the Department of Obstetrics and Gynecology of a single institution between January 2007 and December 2010. Preoperative serum CA 125 levels, ultrasound findings, and menopausal status were noted. In all cases, ultrasound was performed transvaginally with a 6.0 MHz transducer (Acuvix XQ, Medison, Korea); an abdominal scan was also conducted when indicated.
As proposed by Jacobs et al. 7 The distribution of benign and malignant cases by menopausal status, the ultrasound score, and CA 125 is described in Table 2 . In univariate analysis, a significant linear trend for malignancy was found by postmenopausal state, increasing ultrasound score, and increasing CA 125, respectively. The mean serum level of CA 125 was significantly higher among women with malignancies when compared with women with benign lesions (507 U/mL vs 35 U/mL). The sensitivity, specificity, and positive and negative predictive values of different levels of serum CA 125, the ultrasound score, and menopausal status are reported in CA 125 performed better than the ultrasound score and menopausal status, even though the ultrasound score of 2 had more sensitivity than CA 125, but with considerable loss of specificity. The performance of RMI 1 at different cut-off values is shown in Table 3 . The ROC curve evaluation of CA 125, the ultrasound score, and the RMI 1 were all found to be relevant predictors of malignancy. The RMI 1 was found to be statistically significant to the menopausal status (P = 0.001), while were not statistically significant to CA 125 (P = 0.628) and the ultrasound score (P = 0.541).
Discussion
This study was designed to identify the ability of the RMI to correctly identify benign and malignant pelvic masses.
The RMI was originally developed by Jacobs et al. 7 and subsequently the same group reproduced the results in a new group of patients, establishing the superiority of RMI 1 over the individual parameter. 10 The most useful individual criteria in discriminating benign gynecologic lesions from malignant ovarian tumors in the present study were serum CA 125 40 U/mL with a sensitivity of 73.4% and specificity of 83.1%, and an ultrasound score of 2 with a sensitivity of 94.7% and specificity of 62.2%. These results are similar to those of a previous study by Jacobs et al. 7 in 1990, which calculated a sensitivity and specificity of 71% and 75% for CA 125 and sensitivity and specificity of 71% and 83% for an ultrasound score of 2. In the present study menopausal status performed less well than the RMI 1, while CA 125 and the ultra sound score had similar performances. The RMI 1 was a useful preoperative method in the classification of women with pelvic masses into low and high risk for malignancy.
The high sensitivity, specificity, positive predictive value and negative predictive value of 82.1%, 78.1%, 40.6% and 96.0%, respectively found in the present study at a cut-off of 150 is similar to other studies that found that the RMI was a better diagnostic marker in diagnosing ovarian cancer. 10, 17 The previous studies indicate that a RMI 1 of 200 gives the most optimal cut-off, while some authors have suggested a different cut-off value. 7, 11 Using an RMI 1 cut-off of 150, Torres et al. 15 showed a sensitivity and specificity of 79%, and Ulusoy et al. 19 showed a sensitivity, specificity, positive and negative predictive value of 76.4%, 77.9%, 65.9% and 85.5%, respectively, with a 79.4% correct diagnosis rate.
This study showed that a RMI 1 of 150 yields the optimal cut-off value. There are probable reasons to describe the different cut-off values: First, the malignancy prevalence is different. It is well known that, for any test, the positive predictive value will be lower and the negative predictive value higher when used in populations where the disease is uncommon. In our study population, 20.7% of the patients were diagnosed with malignancies while Manjunath et al. 13 reported 61.2% of malignant disease. Second, the lower cutoff value, obtained in our study may be associated with the higher number of malignant cases in the premenopausal group -56.6% in our study versus 19% 7 and 20%. 8 Third, the diagnostic accuracy of a serum CA 125 assay is expected 24 reported that compared to ultrasound, menopausal status, CA 125, CA 19-9, the RMI 4 was fond to be the best predictive method for differentiation of borderline ovary tumor from benign adnexal masses.
Vaginal ultrasound and new scoring system represent the good diagnostic tool for the detection malignant ovary masses. Parameters of new scoring system were wall thickness, number of septum, volume of mass, irregularity, vascularity and echogenicity. The new scoring system had sensitivity 73.9%, specificity 97.7% and negative and positive predictive values of 96.6% and 80.9% respectively. Sensitivity of new scoring system was similar to previous ones but specificity of that is higher. New scoring system shows better to differentiate benign from malignant ovarian mass than four other scoring systems. 25 We have chosen to use the first version The major finding of this study, accepting the RMI 1 cut-off value as 150, is statistically significant diagnostic criteria than menopausal status that discriminate between benign and malignant pelvic masses.
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